ArticleBMJ open2023

Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial.

Xiaorong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.